Cargando…

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases

INTRODUCTION: Pegloticase, a potent uricolytic biologic enzyme, has been shown to be an effective therapeutic option in patients with uncontrolled gout. However, there are limited data on clinical response after a gap in therapy and retreatment with pegloticase. CASE SERIES: This report describes fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morton, Allan H., Hosey, Tony, LaMoreaux, Brian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251856/ https://www.ncbi.nlm.nih.gov/pubmed/29725991 http://dx.doi.org/10.1007/s40744-018-0111-9

Ejemplares similares

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study
por: Albert, John A., et al.
Publicado: (2020)

Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022)

Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
por: Broadwell, Aaron, et al.
Publicado: (2022)

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
por: Botson, John K., et al.
Publicado: (2022)

Use of Pre-Infusion Serum Uric Acid Levels as a Biomarker for Infusion Reaction Risk in Patients on Pegloticase
por: Keenan, Robert T., et al.
Publicado: (2019)

Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices
por: Majjhoo, Amar, et al.
Publicado: (2019)

New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Critical appraisal of the role of pegloticase in the management of gout
por: Ea, Hang-Korng, et al.
Publicado: (2012)

Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
por: Botson, John K., et al.
Publicado: (2023)

A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
por: Alnabwani, Dina, et al.
Publicado: (2022)

Enhancing the Response Rate to Recombinant Uricases in Patients with Gout
por: Schlesinger, Naomi, et al.
Publicado: (2022)

Impact of pegloticase on patient outcomes in refractory gout: current perspectives
por: Cunha, Rita N, et al.
Publicado: (2018)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Systemic Urate Deposition: An Unrecognized Complication of Gout?
por: Khanna, Puja, et al.
Publicado: (2020)

Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013)

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study
por: Botson, John K., et al.
Publicado: (2022)

Comparison Between Early-Onset and Common Gout: A Systematic Literature Review
por: Amatucci, Anthony J., et al.
Publicado: (2023)

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
por: Baraf, Herbert S. B., et al.
Publicado: (2014)

Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study
por: Chen, Sarah K, et al.
Publicado: (2020)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
por: Botson, John K., et al.
Publicado: (2022)

Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study
por: Francis-Sedlak, Megan, et al.
Publicado: (2020)

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
por: Lipsky, Peter E, et al.
Publicado: (2014)

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout
por: Calabrese, Leonard H., et al.
Publicado: (2017)

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
por: Baraf, Herbert SB, et al.
Publicado: (2013)

New-Onset Gout as an Independent Risk Factor for Returning to Dialysis After Kidney Transplantation
por: Li, Justin W., et al.
Publicado: (2020)

Gout mimicking spondyloarthritis: case report and literature review
por: Chen, Wenji, et al.
Publicado: (2017)

A Retrospective Cohort Study of the Effect of Gout on Mortality Among Patients with a History of Kidney Transplantation
por: Li, Justin W., et al.
Publicado: (2020)

PEG-ing down (and preventing?) the cause of pegloticase failure
por: Abeles, Aryeh M
Publicado: (2014)

Comparison of Rates of Lower Extremity Amputation in Patients With and Without Gout in the US Department of Veterans Affairs Health System
por: Mikuls, Ted R., et al.
Publicado: (2022)

Atypical musculoskeletal manifestations of gout in hyperuricemia patients
por: Sakti, Muhammad, et al.
Publicado: (2019)

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
por: Hershfield, Michael S, et al.
Publicado: (2014)

Diaphragmatic hernia repair more than four years after severe trauma: Four case reports
por: de Nadai, Tales Rubens, et al.
Publicado: (2015)

Natural history of COPD: gaps and opportunities
por: Agustí, Alvar, et al.
Publicado: (2017)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

“Gangrenous Finger” Proven to be Acute Gout
por: Gallagher, Eric, et al.
Publicado: (2015)

Retreatment with carboplatin and paclitaxel for recurrent endometrial cancer: A retrospective study of the Memorial Sloan Kettering Cancer Center experience
por: Rubinstein, Maria, et al.
Publicado: (2019)

Apparent spontaneous regression of malignant neoplasms after radiography: Report of four cases
por: Sasaki, Jun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7fhb58teum4eridgcktopqfsjf